Catalyst Pharmaceuticals Inc (CPRX)
22.75
+0.82
(+3.74%)
USD |
NASDAQ |
Nov 27, 14:07
Catalyst Pharmaceuticals Cash from Operations (Quarterly): 72.87M for Sept. 30, 2024
Cash from Operations (Quarterly) Chart
Historical Cash from Operations (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2024 | 72.87M |
| June 30, 2024 | 64.14M |
| March 31, 2024 | 31.92M |
| December 31, 2023 | 55.65M |
| September 30, 2023 | 45.13M |
| June 30, 2023 | 30.75M |
| March 31, 2023 | 12.07M |
| December 31, 2022 | 40.08M |
| September 30, 2022 | 41.30M |
| June 30, 2022 | 26.19M |
| March 31, 2022 | 8.478M |
| December 31, 2021 | 19.18M |
| September 30, 2021 | 21.71M |
| June 30, 2021 | 15.68M |
| March 31, 2021 | 3.814M |
| December 31, 2020 | 13.10M |
| September 30, 2020 | 11.45M |
| June 30, 2020 | 13.26M |
| March 31, 2020 | 7.213M |
| December 31, 2019 | 12.29M |
| September 30, 2019 | 16.26M |
| June 30, 2019 | 14.07M |
| March 31, 2019 | -8.016M |
| December 31, 2018 | -8.352M |
| September 30, 2018 | -6.953M |
| Date | Value |
|---|---|
| June 30, 2018 | -4.762M |
| March 31, 2018 | -6.082M |
| December 31, 2017 | -4.030M |
| September 30, 2017 | -2.633M |
| June 30, 2017 | -3.201M |
| March 31, 2017 | -3.879M |
| December 31, 2016 | -4.412M |
| September 30, 2016 | -3.278M |
| June 30, 2016 | -4.344M |
| March 31, 2016 | -5.930M |
| December 31, 2015 | -4.631M |
| September 30, 2015 | -5.343M |
| June 30, 2015 | -4.246M |
| March 31, 2015 | -3.795M |
| December 31, 2014 | -3.98M |
| September 30, 2014 | -3.553M |
| June 30, 2014 | -2.984M |
| March 31, 2014 | -2.425M |
| December 31, 2013 | -4.130M |
| September 30, 2013 | -1.684M |
| June 30, 2013 | -1.812M |
| March 31, 2013 | -2.249M |
| December 31, 2012 | -1.594M |
| September 30, 2012 | -1.101M |
| June 30, 2012 | -1.144M |
Cash From Operations Definition
Cash flow from operations is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall operating activities of the company. A few examples of operating activities include change in receivables, change in inventories, and changes in current assets.
Cash from Operations (Quarterly) Range, Past 5 Years
3.814M
Minimum
Mar 2021
72.87M
Maximum
Sep 2024
27.31M
Average
20.44M
Median
Cash from Operations (Quarterly) Benchmarks
| Corcept Therapeutics Inc | 73.83M |
| Vertex Pharmaceuticals Inc | 1.370B |
| Sarepta Therapeutics Inc | -70.70M |
| ADMA Biologics Inc | 25.03M |
| BioVie Inc | -3.580M |
Cash from Operations (Quarterly) Related Metrics
| Cash from Investing (Quarterly) | -0.259M |
| Cash from Financing (Quarterly) | -5.974M |
| Free Cash Flow | 221.79M |
| Free Cash Flow Per Share (Quarterly) | 0.579 |
| Free Cash Flow to Equity (Quarterly) | 72.61M |
| Free Cash Flow to Firm (Quarterly) | 72.61M |
| Free Cash Flow Yield | 8.00% |